BioSpace News Archive

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today presented new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that two posters on BXCL701, the Company’s investigational, oral innate immunity activator, will be presented at the Society for Immunotherapy of Cancer’s (“SITC”) 35th Anniversary Annual Meeting

Homology Medicines, Inc., a genetic medicines company, announced that Pfizer Inc. has agreed to make a $60 million equity investment in Homology.

Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Promtheus’ 360 platform

Collaboration Seeks to Enhance Response Rate and Identify Biomarker for Treatment of NASH and Fibrosis

$60.0 million Series A funding completed by Asia-Pacific subsidiary, BioShin to bring NURTEC™ ODT to an estimated 80 million migraine sufferers in China

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, announced its financial results for the third quarter ended September 30, 2020.

ProMIS Neurosciences, Inc. commented on the November 6th FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting and its review of Biogen’s Biologics License Application for aducanumab for the treatment of Alzheimer’s disease.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the third quarter ended September 30, 2020.